Explainer: How worried should we be about blood clots linked to AstraZeneca, J&J vaccines?
By
Friday May 28, 2021
ZURICH: International drug regulators have said the benefits of using COVID-19 vaccines developed by Johnson & Johnson and AstraZeneca outweigh risks as they investigate reports of extremely rare, but potentially fatal blood clots.
Several EU countries have restricted their use.
Amid concerns that reports of rare side-effects could undermine vaccine confidence, experts have emphasised that clotting risks for both shots remain extremely low and the vaccines are highly effective in preventing COVID-19 deaths and severe disease.
Here s what we know so far:
WHAT HAS HAPPENED?
Amid concerns that reports of rare side-effects could undermine vaccine confidence, experts have emphasised that clotting risks for both shots remain extremely low and the vaccines are highly effective in preventing COVID-19 deaths and severe disease.
U.S. regulators have recommended pausing the use of Johnson & Johnson's (JNJ.N) COVID-19 vaccine, as they investigate rare blood clotting in six women.
Amid concerns that reports of rare side-effects could undermine vaccine confidence, experts have emphasised that clotting risks for both shots remain extremely low and the vaccines are highly effective in preventing COVID-19 deaths and severe disease
International drug regulators have said the benefits of using COVID-19 vaccines developed by Johnson & Johnson and AstraZeneca outweigh risks as they investigate reports of extremely rare, but potentially fatal blood clots.